Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. RKLB

Go back to Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Regeneron (NASDAQ: REGN) Delayed: 632.90 +12.76 (2.06%)
Previous Close $620.14    52 Week High $592.36 
Open $623.64    52 Week Low $325.35 
Day High $638.76    P/E 166.12 
Day Low $623.44    EPS $3.81 
Volume 1,213,632